Cytogenetic and molecular heterogeneity of 7q36/12p13 rearrangements in childhood AML

Leukemia

Volumn 16, Issue 12, 2002, Pages 2408-2416

  Simmons, H M ^a   Oseth, L ^b   Nguyen, P ^b   O'Leary, M ^a   Conklin, K F ^a   Hirsch, B ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

AML; ETV6; t(7; 12); TEL

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BASE PAIRING; CASE REPORT; CENTROMERE; CHILD; CHILDHOOD LEUKEMIA; CHROMOSOME 12; CHROMOSOME 12P; CHROMOSOME 7Q; CHROMOSOME BREAKAGE; CHROMOSOME INSERTION; CHROMOSOME MAP; CHROMOSOME REARRANGEMENT; CHROMOSOME TRANSLOCATION 12; CHROMOSOME TRANSLOCATION 7; CYTOGENETICS; GENE FUSION; GENE IDENTIFICATION; GENE INACTIVATION; GENE SEQUENCE; GENETIC HETEROGENEITY; GENETIC ORGANIZATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN GENOME; INTRON; MALE; MOLECULAR CLONING; PRIORITY JOURNAL; RECIPROCAL CHROMOSOME TRANSLOCATION; REGULATORY MECHANISM; TELOMERE;

EID: 0036941196     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402773     Document Type: Article

References (34)

1. Slater RM, von Drunen E, Kroes WG, Weghuis DO, van den Berg E, Smit EM, van der Does-van den Berg A, van Wering E, Hahlen K, Carroll AJ, Raimondi SC, Beverloo HB. t(7;12)(q36;p13) and t(7;12)(q32;p13) - translocations involving ETV6 in children 18 months of age or younger with myeloid disorders. Leukemia 2001; 15: 915-920.
2. Tosi S, Harbott J, Teigler-Schlegel A, Haas OA, Pirc-Danoewinata H, Harrison CJ, Biondi A, Cazzaniga G, Kempski H, Scherer SW, Kearney L. t(7;12)(q36;p13), a new recurrent translocation involving ETV6 in infant leukemia. Genes Chromos Cancer 2000; 29: 325-332.
3. Wlodarska I, La Starza R, Baens M, Dierlamm J, Uyttebroeck A, Selleslag D, Francine A, Mecucci C, Hagemeijer A, Van den Berghe H, Marynen P. Fluorescence in situ hybridization characterization of new translocations involving TEL (ETV6) in a wide spectrum of hematologic malignancies. Blood 1998; 91: 1399-1406.
4. Satake N, Maseki N, Nishiyama M, Kobayashi H, Sakurai M, Inaba H, Katano N, Horikoshi Y, Eguchi H, Miyake M, Seto M, Kaneko Y. Chromosome abnormalities and MLL rearrangements in acute myeloid leukemia of infants. Leukemia 1999; 13: 1013-1017.
5. Beverloo HB, Panagopoulos I, Isaksson M, van Wering E, van Drunen E, de Klein A, Johansson B, Slater R. Fusion of the homeobox gene HLXB9 and the ETV6 gene in infant acute myeloid leukemias with the t(7;12)(q36;p13). Cancer Res 2001; 61: 5374-5377.
6. Chakrabarti SR, Nucifora G. The leukemia-associated gene TEL encodes a transcription repressor which associates with SMRT and mSin3A. Biochem Biophys Res Commun 1999; 264: 871-877.
7. Lopez RG, Carron C, Oury C, Gardellin P, Bernard O, Ghysdael J. TEL is a sequence-specific transcriptional repressor. J Biol Chem 1999; 274: 30132-30138.
8. Fenrick R, Wang L, Nip J, Amann JM, Rooney RJ, Walker-Daniels J, Crawford HC, Hulboy DL, Kinch MS, Matrisian LM, Hiebert SW. TEL, a putative tumor suppressor, modulates cell growth and cell morphology of ras-transformed cells while repressing the transcription of stromelysin-1. Mol Cell Biol 2000; 20: 5828-5839.
9. Wang LC, Kuo F, Fujiwara Y, Gilliland DG, Golub TR, Orkin SH. Yolk sac angiogenic defect and intra-embryonic apoptosis in mice lacking the Ets-related factor TEL. Embo J 1997; 16: 4374-4383.
10. Wang LC, Swat W, Fujiwara Y, Davidson L, Visvader J, Kuo F, Alt FW, Gilliland DG, Golub TR, Orkin SH. The TEL/ETV6 gene is required specifically for hematopoiesis in the bone marrow. Genes Dev 1998; 12: 2392-2402.
11. Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 1994; 77: 307-316.
12. Odero MD, Carlson K, Calasanz MJ, Lahortiga I, Chinwalla V, Rowley JD. Identification of new translocations involving FTV6 in hematologic malignancies by fluorescence in situ hybridization and spectral karyotyping. Genes Chromos Cancer 2001; 31: 134-142.
13. Rowley JD. The role of chromosome translocations in leukemogenesis. Semin Hematol 1999; 36 (Suppl. 7): 59-72.
14. Golub TR, Barker GF, Stegmaier K, Gilliland DG. Involvement of the TEL gene in hematologic malignancy by diverse molecular genetic mechanisms. Curr Top Microbiol Immunol 1996; 211: 279-288.
15. Golub TR, Barker GF, Stegmaier K, Gilliland DG. The TEL gene contributes to the pathogenesis of myeloid and lymphoid leukemias by diverse molecular genetic mechanisms. Curr Top Microbiol Immunol 1997; 220: 67-79.
16. Kuno Y, Abe A, Emi N, Iida M, Yokozawa T, Towatari M, Tanimoto M, Saito H. Constitutive kinase activation of the TEL-Syk fusion gene in myelodysplastic syndrome with t(9;12)(q22;p12). Blood 2001; 97: 1050-1055.
17. Lacronique V, Boureux A, Valle VD, Poirel H, Quang CT, Mauchauffe M, Berthou C, Lessard M, Berger R, Ghysdael J, Bernard OA. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 1997; 278: 1309-1312.
18. Papadopoulos P, Ridge SA, Boucher CA, Stocking C, Wiedemann LM. The novel activation of ABL by fusion to an ets-related gene, TEL. Cancer Res 1995; 55: 34-38.
19. Peeters P, Raynaud SD, Cools J, Wlodarska I, Grosgeorge J, Philip P, Monpoux F, Van Rompaey L, Baens M, Van den Berghe H, Marynen P. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood 1997; 90: 2535-2540.
20. Schwaller J, Frantsve J, Aster J, Williams IR, Tomasson MH, Ross TS, Peeters P, Van Rompaey L, Van Etten RA, Ilaria R Jr, Marynen P, Gilliland DG. Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes. EMBO J 1998; 17: 5321-5333.
21. Yagasaki F, Wakao D, Yokoyama Y, Uchida Y, Murohashi I, Kayano H, Taniwaki M, Matsuda A, Bessho M. Fusion of ETV6 to fibroblast growth factor receptor 3 in peripheral T-cell lymphoma with a t(4;12)(p16;p13) chromosomal translocation. Cancer Res 2001; 61: 8371-8374.
22. Suto Y, Sato Y, Smith SD, Rowley JD, Bohlander SK. A t(6;12)(q23;p13) results in the fusion of ETV6 to a novel gene, STL, in a B-cell ALL cell line. Genes Chromos Cancer 1997; 18: 254-268.
23. Yagasaki F, Jinnai I, Yoshida S, Yokoyama Y, Matsuda A, Kusumoto S, Kobayashi H, Terasaki H, Ohyashiki K, Asou N, Murohashi I, Bessho M, Hirashima K. Fusion of TEL/ETV6 to a novel ACS2 in myelodysplastic syndrome and acute myelogenous leukemia with t(5;12)(q31;p13). Genes Chromos Cancer 1999; 26: 192-202.
24. Cools J, Mentens N, Odero MD, Peeters P, Wlodarska I, Delforge M, Hagemeijer A, Marynen P. Evidence for position effects as a variant ETV6-mediated leukemogenic mechanism in myeloid leukemias with a t(4;12)(q11-q12;p13) or t(5;12)(q31;p13). Blood 2002; 99: 1776-1784.
25. ISCN (1995). An International System for Human Cytogenetic Nomenclature. S Karger, Basel, 1995.
26. Fink JM, Dobyns WB, Guerrini R, Hirsch BA. Identification of a duplication of Xq28 associated with bilateral periventricular nodular heterotopia. Am J Hum Genet 1997; 61: 379-387.
27. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon, 2001.
28. Nucifora G. The EVI1 gene in myeloid leukemia. Leukemia 1997; 11: 2022-2031.
29. Peeters P, Wlodarska I, Baens M, Criel A, Selleslag D, Hagemeijer A, Van den Berghe H, Marynen P. Fusion of ETV6 to MDS1/EVI1 as a result of t(3;12)(q26;p13) in myeloproliferative disorders. Cancer Res 1997; 57: 564-569.
30. Pekarsky Y, Rynditch A, Wieser R, Fonatsch C, Gardiner K. Activation of a novel gene in 3q21 and identification of intergenic fusion transcripts with ecotropic viral insertion site I in leukemia. Cancer Res 1997; 57: 3914-3919.
31. Jacks T, Shih TS, Schmitt EM, Bronson RT, Bernards A, Weinberg RA. Tumour predisposition in mice heterozygous for a targeted mutation in Nf1. Nat Genet 1994; 7: 353-361.
32. Fero ML, Randel E, Gurley KE, Roberts JM, Kemp CJ. The murine gene p27Kip1 is haploinsufficient for tumour suppression. Nature 1998; 396: 177-180.
33. Venkatachalam S, Shi YP, Jones SN, Vogel H, Bradley A, Pinkel D, Donehower LA. Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation. EMBO J 1998; 17: 4657-4667.
34. Shannon KM, Le Beau MM, Largaespada DA, Killeen N. Modeling myeloid leukemia tumor suppressor gene inactivation in the mouse. Semin Cancer Biol 2001; 11: 191-200.